These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 19291801)

  • 41. The triple-negative (CD34-/HLA-DR-/CD11b-) profile rapidly and specifically identifies an acute promyelocytic leukemia.
    Rahman K; Gupta R; Singh MK; Sarkar MK; Gupta A; Nityanand S
    Int J Lab Hematol; 2018 Apr; 40(2):144-151. PubMed ID: 28984423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical analysis of HLA-DR-negative non-M3 AML].
    Mori H; Sakai H; Sanada M; Shimamoto K; Sasaki S; Azuma R; Higuchi T; Harada H; Niikura H; Omine M; Fujita K; Takahashi N
    Rinsho Ketsueki; 2007 Jul; 48(7):547-53. PubMed ID: 17695303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis.
    Kaito K; Katayama T; Masuoka H; Nishiwaki K; Sano K; Sekiguchi N; Hagino T; Kobayashi M
    Clin Lab Haematol; 2005 Oct; 27(5):307-11. PubMed ID: 16178910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.
    Zheng J; Wang X; Hu Y; Yang J; Liu J; He Y; Gong Q; Yao J; Li X; Du W; Huang S
    Cytometry B Clin Cytom; 2008 Jan; 74(1):25-9. PubMed ID: 18061959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia.
    Nie L; Ma R; Yuan X; Jiang L; Yang S; Xu H; Liu X; Liu Y; Zhang L; Zhu Z
    Leuk Lymphoma; 2020 Oct; 61(10):2482-2487. PubMed ID: 32476519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry.
    Fang H; Wang SA; Hu S; Konoplev SN; Mo H; Liu W; Zuo Z; Xu J; Jorgensen JL; Yin CC; El Hussein S; Jelloul FZ; Tang Z; Medeiros LJ; Wang W
    Cytometry B Clin Cytom; 2022 Jul; 102(4):283-291. PubMed ID: 35716019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for early hematopoietic progenitor cell involvement in acute promyelocytic leukemia.
    Edwards RH; Wasik MA; Finan J; Rodriguez R; Moore J; Kamoun M; Rennert H; Bird J; Nowell PC; Salhany KE
    Am J Clin Pathol; 1999 Dec; 112(6):819-27. PubMed ID: 10587705
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
    Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T; Kern W
    Cytometry B Clin Cytom; 2004 Nov; 62(1):25-38. PubMed ID: 15468339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leukemias resembling acute promyelocytic leukemia, microgranular variant.
    Nagendra S; Meyerson H; Skallerud G; Rosenthal N
    Am J Clin Pathol; 2002 Apr; 117(4):651-7. PubMed ID: 11939742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FLT3 overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or codon 835-836 mutations: a pilot study.
    Lilakos K; Viniou NA; Mavrogianni D; Vassilakopoulos TP; Dimopoulou MN; Plata E; Angelopoulou MK; Variami E; Stavrogianni N; Liapi D; Xilouri I; Galanopoulos A; Ageloudi M; Panayiotidis P; Voulgarelis M; Rombos J; Meletis J; Yataganas X; Pangalis GA
    Anticancer Res; 2006; 26(2A):1201-7. PubMed ID: 16619525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The "typical" immunophenotype of acute promyelocytic leukemia (APL-M3): does it prove true for the M3-variant?
    Exner M; Thalhammer R; Kapiotis S; Mitterbauer G; Knöbl P; Haas OA; Jäger U; Schwarzinger I
    Cytometry; 2000 Apr; 42(2):106-9. PubMed ID: 10797447
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinicopathological features in HLA-DR-negative acute myeloid leukemia].
    Muroi K; Yoshida M; Suzuki T; Amemiya Y; Hatake K; Miura Y
    Rinsho Ketsueki; 1997 Aug; 38(8):631-7. PubMed ID: 9311267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia].
    Wang YZ; Chang Y; Zhu HH; Qin YZ; Li JL; Fu JY; Li LD; Chen SS; Huang XJ; Lu DP; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):427-32. PubMed ID: 16800913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular characteristics and chromatin texture features in acute promyelocytic leukemia.
    De Mello MR; Albuquerque DM; Pereira-Cunha FG; Albanez KB; Pagnano KB; Costa FF; Metze K; Lorand-Metze I
    Diagn Pathol; 2012 Jun; 7():75. PubMed ID: 22742960
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genomewide array-based comparative genomic hybridization analysis of acute promyelocytic leukemia.
    Karnan S; Tsuzuki S; Kiyoi H; Tagawa H; Ueda R; Seto M; Naoe T
    Genes Chromosomes Cancer; 2006 Apr; 45(4):420-5. PubMed ID: 16419057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia.
    Lee JJ; Cho D; Chung IJ; Cho SH; Park KS; Park MR; Ryang DW; Kim HJ
    Am J Hematol; 2003 Jul; 73(3):149-53. PubMed ID: 12827650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias.
    Lewis RE; Cruse JM; Webb RN; Sanders CM; Beason K
    Exp Mol Pathol; 2007 Oct; 83(2):269-73. PubMed ID: 17603036
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression.
    Syampurnawati M; Tatsumi E; Furuta K; Takenokuchi M; Nakamachi Y; Kawano S; Kumagai S; Saigo K; Matsui T; Takahashi T; Nagai K; Yabe H; Kondo S; Hayashi Y
    Leuk Res; 2007 Jul; 31(7):921-9. PubMed ID: 17056111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome.
    Sellar RS; Gale RE; Khwaja A; Garbowski M; Loddo M; Stoeber K; Williams GH; Linch DC
    Br J Haematol; 2018 May; 181(4):486-494. PubMed ID: 29676467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.